mardi 24 juillet 2012

FDA approves Kyprolis for some patients with multiple myeloma

            The U.S. Food and Drug Administration recently approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy.

            A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones. The bone marrow is where normal blood cells are produced.

Aucun commentaire:

Enregistrer un commentaire